Choose your language

Company

Farmabios manufactures and markets active ingredients for pharmaceutical applications and provides custom synthesis services

Details

Technologies

A wide range of advanced proprietary technologies in accordance with GMP standards and Pharmacopeas specifications.

Details

Events

No events

Details

History

  • 2014
    As of 28 of March, with agreement for the contribution in kind of shares to the capital reserves executed between ZELLBIOS SA, ZELLBIOS GMBH e PHARMAZELL GMBH, Pharmazell Gmbh is the sole shareholder of Farmabios SPA.

  • 2013
    DPE (Deutsche Private Equity GmbH) acquires Zellbios from Ergon Capital Partners II.

  • 2011
    Completation of Antineoplastics Plant (July)
    Zellbios SA acquires Pharmazell, company headquartered in Raubling (Germany) which manufactures and trades active pharmaceutical ingredients.

  • 2010
    Incorporation of Farmabios USA destined to operate as Commercial Office.
    Building of Antineoplastics Plant.
    Completation of one of the only few plants in the world producing sterile steroids for crystallization, including a department for micronization under aseptic conditions.
    Ergon Capital Partners II SA incorporates the holding Farmabios International SA (henceforth Zellbios SA), transferring its Farmabios shares to it.

  • 2007
    Acquisition of Farmabios by Ergon Capital 115k a holding company for shareholders interested in investing in market leader companies with a sustainable competitive advantage and high growth potential, established in 2005 by "Group Bruxelles Lambert" (http://en.gblbe) and "Pa rcom Ventures", latter being part of the ING Group.
    Audit and preliminary approval for the development of new products.

  • 2005
    Successful initial audit by the EDQM.

  • 2004
    Obtained AIM approval for a new multipurpose plant for the production of High Potency Drugs.
    IDA FDA audit and preliminary approval for the development of new products.

  • 2003
    Implementation of a program to monitor and limit environmental impact.

  • 2002
    Obtained ISO 9001 and 14001 certifications.
    Establishment of the "Prometeo" consortium for the creation of a production plant for the manufacturing of nanoparticles using a technology based on supercritical gases by Farmabios, Micro Macinazione SA and Micro Nano Materials (Salerno University).
    Doubling of steroid manufacturing capacity thanks to the establishment of a new plant that utilizes a totally automated process controlled by advanced software.

  • 2000
    FDA audit and preliminary approval for the development of new products.
    Commissioning of a new pilot plant for the manufacturing of antibiotics.

  • 1997
    FDA audit and approval.
    Doubling of the production plants for the manufacturing of oral and sterile antibiotics.

  • 1995
    Introduction of sterile crystallized products into the cephalosporins production line, thanks to a special sterile crystallization plant.

  • 1990
    Entry into the cephalosporins sector with the inauguration of the new plant for manufacturing oral products.

  • 1985
    Dismission of the production of vitamin B12 derivatives and doubling of production capacity.

  • 1981
    Acquisition by another Group intending to expand operations and the existing product list.

  • 1967
    Relocation to the current premises and name change to Farmabios.

  • 1961
    Founding of Farmabios and commencement of the manufacturing of steroids and vitamin B12 derivatives.